Effectiveness of monovalent rotavirus vaccine among young children in Pakistan: a test-negative case-control

Syed Asad Ali1, Shazia Sultana1, Atif Riaz1

  • 1Aga Khan University, Karachi, Pakistan.

Vaccine
|April 25, 2026
PubMed

Insights

Two doses of the Rotarix (RV1) vaccine offer fair protection against rotavirus disease in Pakistan, a high-burden country. Further vaccination strategies are recommended for continued disease reduction.

Area of Science:

  • Pediatric Infectious Diseases
  • Vaccinology
  • Public Health Surveillance

Background:

  • Pakistan faces a high burden of childhood rotavirus mortality.
  • The monovalent oral rotavirus vaccine, Rotarix (RV1), was introduced into the national immunization program in 2017.
  • A two-dose schedule is administered at 6 and 10 weeks of age.

Purpose of the Study:

  • To evaluate the effectiveness of the Rotarix (RV1) vaccine in preventing severe rotavirus gastroenteritis requiring hospitalization.
  • To assess vaccine effectiveness in a real-world setting in Pakistan.

Main Methods:

  • Active surveillance for rotavirus gastroenteritis was conducted in 9 hospitals across 3 provinces from April 2018 to March 2023.
  • Children eligible for vaccination were enrolled; cases tested positive for rotavirus, and controls tested negative via enzyme immunoassay (EIA).
  • Unconditional logistic regression was used to estimate the effectiveness of two RV1 doses versus zero doses.

Main Results:

  • The study analyzed 517 rotavirus cases and 1310 controls among children with available vaccination data.
  • Two RV1 doses showed 33% effectiveness against hospital care for rotavirus in children aged 22 weeks-11 months.
  • Effectiveness was higher (45%) in better-nourished children and varied by rotavirus genotype detected.

Conclusions:

  • Two doses of RV1 provide moderate protection in a high rotavirus burden setting like Pakistan.
  • Continued pursuit of additional vaccination strategies is crucial for further reducing rotavirus disease burden.
  • The findings underscore the importance of ongoing vaccine efficacy monitoring and strategy refinement.
Abstract